Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 14/20 | 0.67 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.67 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.67 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.67 |
| ▸ | TSHR | P16473 | 1/20 | 0.67 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.67 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12648456 | 1.00 | SIGMAR1 (0.67) | SIGMAR1CYP1A2CYP3A4CYP2D6TSHR | |
| SCHEMBL11457646 | 0.88 | OPRK1 (0.61) | SIGMAR1CYP1A2CYP3A4CYP2D6TSHR | |
| SCHEMBL11457647 | 0.88 | OPRK1 (0.61) | SIGMAR1CYP1A2CYP3A4CYP2D6TSHR | |
| SCHEMBL9001750 | 0.85 | PDK2 (0.46) | SIGMAR1CYP1A2CYP3A4CYP2D6TSHR | |
| SCHEMBL11457294 | 0.84 | SIGMAR1 (0.65) | SIGMAR1CYP1A2CYP3A4CYP2D6TSHR | |
| SCHEMBL11453589 | 0.83 | SIGMAR1 (0.63) | SIGMAR1CYP1A2CYP3A4CYP2D6TSHR | |
| SCHEMBL11453590 | 0.83 | SIGMAR1 (0.63) | SIGMAR1CYP1A2CYP3A4CYP2D6TSHR | |
| SCHEMBL11610023 | 0.80 | SIGMAR1 (1.00) | SIGMAR1CYP1A2CYP3A4CYP2D6TSHR | |
| SCHEMBL7218504 | 0.80 | SIGMAR1 (1.00) | SIGMAR1CYP1A2CYP3A4CYP2D6TSHR | |
| SCHEMBL7218502 | 0.80 | SIGMAR1 (1.00) | SIGMAR1CYP1A2CYP3A4CYP2D6TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10167295-B2 | Analgesic compounds and methods of use | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2019-01-01 | — | — | US | disclosed |
| US-20160068541-A1 | ANALGESIC COMPOUNDS AND METHODS OF USE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-03-10 | — | — | US | disclosed |
| US-20160068541-A1 | ANALGESIC COMPOUNDS AND METHODS OF USE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-03-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160068541-A1 | ANALGESIC COMPOUNDS AND METHODS OF USE | OPRL1, OPRK1, ACHE | SIGMAR1 96/4885CYP1A2 169/4885CYP3A4 378/4885 |
| US-10167295-B2 | Analgesic compounds and methods of use | OPRL1, OPRK1, ACHE | SIGMAR1 96/4885CYP1A2 169/4885CYP3A4 378/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.